You must be 18 or older — and of legal age in your province — to enter. All products are sold strictly for laboratory research use only and are not for human or veterinary consumption.
By entering you confirm you are a qualified buyer of research materials and agree to our Terms and Research-Use Policy.
Neuropeptides and neuroscience research: Semax and Selank, DSIP, VIP, pinealon, cerebrolysin, the melanocortin system and neurotrophic factors, and what the evidence does and does not show.
What NGF and BDNF are, why precursor forms do the opposite of mature ones, why adult human neurogenesis is still contested, and exactly what the published Semax, Selank and P021 work measured.
What alpha-MSH is, how one precursor protein yields it alongside ACTH and beta-endorphin, what each of the five melanocortin receptors actually responds to, and where KPV fits as its C-terminal fragment.
What Cerebrolysin is, why a mixture of brain-derived peptides cannot be characterised like a single research peptide, and what the Cochrane reviews of stroke and vascular dementia actually concluded.
Neuropeptides explained: how they differ from classic neurotransmitters, the major families from endorphins to orexin, and which ones researchers study.
Vasoactive intestinal peptide (VIP) explained: the 28-amino-acid neuropeptide found in 1970, its VPAC receptors, what it does, and sourcing in Canada.
Pinealon explained: the Glu-Asp-Arg tripeptide from St. Petersburg's bioregulator programme, its cell and rat studies, and sourcing in Canada.
Nootropic peptides explained: Semax, Selank, P021, PE-22-28 and DSIP compared by origin, mechanism and evidence, plus sourcing in Canada.
DSIP explained: the 1977 rabbit sleep peptide with no known gene or receptor, what studies found, why results conflict, and sourcing in Canada.
Semax vs Selank: two Russian-developed heptapeptides with the same Pro-Gly-Pro tail. What each is built from, what studies found, and Canadian sourcing.